Hypogonadism in chronic obstructive pulmonary disease (COPD)  – risk factors

Ljiljana Novkovic; Zorica Lazic; Marina Petrovic; Vojislav Cupurdija; Katarina Vujanac; Ivan Cekerevac

doi:10.2298/VSP170312081N

Ljiljana Novkovic University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Internal medicine
Zorica Lazic University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Internal medicine
Marina Petrovic University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Internal medicine
Vojislav Cupurdija University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Internal medicine
Katarina Vujanac Clinical Center Kragujevac Clinic for pulmonary diseases
Ivan Cekerevac University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Internal medicine

DOI: https://doi.org/10.2298/VSP170312081N

Keywords: hypogonadism, pulmonary disease, chronic obstructive, risk factors

Abstract

Abstract

Bacground/Aim. Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality in pulmonary pathology. However, apart from its own pulmonary manifestations, this disease is also characterized by systemic effects, including hypogonadism which is described especially in the group of men with COPD. The aim of this study was to evaluate risk factors for hypogonadism in men with COPD. Methods. The study included 96 male patients with COPD in stable phase of the disease. All patients were checked for concentration of free testosterone in serum, markers of systemic inflammation, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and C reactive protein (CRP), pulmonary function test, gas exchange parameters, a 6-minute walk test (6MWT), nutritional status and condition of skeletal muscle (midthigh muscle cross-sectional area – MTCSA using computed tomography). Results. Decreased value of free testosterone was found in 37.5% of the patients. In the group with hypogonadism (free testosterone < 4.5 pg/mL), we found significantly increased serum concentration of TNF-α (5.88 ± 3.21 vs. 3.16 ± 2.53 pg/mL; p < 0.05), significantly lower MTSCA (68.2 ± 18.72 vs. 91.1 ± 21.4 cm²; p < 0.05) and the 6MWT (268.33 ± 32.35 vs. 334.25 ± 43.25 m; p < 0.05). Lung function, gas exchange markers and body mass index (BMI) were similar in both groups. The multivariate regression analysis singled out serum value of TNF-α as an independent predictor of serum concentrations of free testosterone (B = -0.157; 95% confidence interval: -0.262–0.053). Conclusion. In our analysis we found that TNF-α as a marker of systemic inflammation is an independent predictor of the presence of hypogonadism in the patients with COPD. Our results indicate that hypogonadism predisposes to skeletal muscle wasting and exercise intolerance in male COPD patients.

References

REFERENCES

Choudhury G, Rabinovich R, MacNee W. Comorbidities and sys-temic effects of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35(1): 101–30.

Vertkin AL, Morgunov LIu, Shakhmanaev KhA. Hypogonadism and chronic obstructive pulmonary disease. Urologiia 2013; (5): 116–8, 120–2. (Russian)

Snyder PJ. Hypogonadism in elderly men: What to do until the evidence comes. N Engl J Med 2004; 350(5): 440–2.

Laghi F. Low testosterone in chronic obstructive pulmonary dis¬ease: Does it really matter. Am J Respir Crit Care Med 2005; 172(9): 1069–70.

Balasubramanian V, Naing S. Hypogonadism in chronic ob-struc¬tive pulmonary disease: incidence and effects. Curr Opin Pulm Med 2012; 18(2): 112–7.

Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Pu-thu¬cheary ZA, et al. Quadriceps wasting and physical inactiv¬ity in patients with COPD. Eur Respir J 2012; 40(5): 1115–22.

Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol In-vest 2005; 28(3 Suppl): 14–22.

Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE, Jubran A, et al. Hypogonadism in men with chronic obstructive pul-monary disease: Prevalence and quality of life. Am J Respir Crit Care Med 2005; 171(7): 728–33.

Karadag F, Ozcan H, Karul AB, Yilmaz M, Cildag O. Sex hor-mone alterations and systemic inflammation in chronic ob-structive pulmonary disease. Int J Clin Pract 2009; 63(2): 275–81.

Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A, LeB-lanc P, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124(1): 83–9.

Barker BL, McKenna S, Mistry V, Pancholi M, Patel H, Haldar K, et al. Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 975–81.

Ferrari R, Caram LM, Faganello MM, Sanchez FF, Tanni SE, Godoy I. Relation between systemic inflammatory markers, pe-ripheral muscle mass, and strength in limb muscles in stable COPD patients. Int J Chron Obstruct Pulmon Dis 2015; 10: 1553–8.

Daabis RG, Rehem RN, Hassan MM, Khalil GI. Hypogonadism in patients with chronic obstructive pulmonary disease: Rela-tionship with airflow limitation, muscle weakness and systemic inflammation. Alex J Med 2016; 52(1): 27–33.

Van Vliet M, Spruit MA, Verleden G, Kasran A, van Herck E, Pitta F, et al. Hypogonadism, quadriceps weakness, and exer-cise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(9): 1105–11.

Zohal MA, Hashemipour S, Karamali N, Farzam SA, Sami R. Asso¬ciation of hypogonadism with the severity of chronic ob-structive pulmonary disease. JQUMS 2015; 19(4): 19–24.

Shaker A, El-Shora A, El-Gammal M, Labib HA. Endocrinal dis¬turbances and systemic inflammatiom in chronic obstruc-tive pulmonary disease (COPD). Egypt J Chest Dis Tuber 2012; 61(3): 81–8.

Laghi F, Langbein EW, Antonescu-Turcu A, Jubran A, Bammert C, Tobin MJ. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171(6): 598–605.

Kaparianos A, Argyropoulou E, Efremidis G, Spiropoulos K. Sex hor¬mone alterations and systemic inflammation in a group of male COPD smokers and their correlation with the +138 in-sA/delA endothelin-1 gene polymorphism. A case-control study. Eur Rev Med Pharmacol Sci 2011; 15(10): 1149–57.

Čekerevac I, Lazić Z, Novković LJ, Petrović M, Ćupurdija V, Kitano¬vić G, et al. Exercise tolerance and dyspnea in patients with chronic obstructive pulmonary disease. Vojnosanit Pregl 2009; 67(1): 36–41. (Serbian)